Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Celadon Pharmaceuticals PLC ( (GB:CEL) ).
Celadon Pharmaceuticals Plc announced the successful passing of all resolutions at its recent Annual General Meeting. Despite the low turnout of shares voted, the board plans to engage with shareholders who opposed certain resolutions. Additionally, the company has entered into a debt facility and expects to receive £1.0 million within three days, which will facilitate its delisting process. Chairman Alexander Anton has indicated he may resign if the delisting is approved, following a review of his position.
More about Celadon Pharmaceuticals PLC
Celadon Pharmaceuticals Plc is a UK-based pharmaceutical company specializing in the development, production, and sale of innovative cannabis-based medicines. The company focuses on improving the quality of life for chronic pain sufferers and exploring cannabis-based treatments for conditions like autism. Celadon operates a 100,000 sq. ft EU-GMP approved facility in the UK, which includes indoor hydroponic cultivation, proprietary GMP extraction, and an analytical and R&D laboratory. The company holds a Home Office license for the commercial supply of pharmaceutical-grade cannabis products and owns an approved clinical trial for treating chronic pain. Celadon also has a minority interest in Kingdom Therapeutics, which is developing a cannabinoid medicine for Autism Spectrum Disorder.
Average Trading Volume: 165,388
Technical Sentiment Signal: Sell
Current Market Cap: £7.92M
Find detailed analytics on CEL stock on TipRanks’ Stock Analysis page.